Back to top
more

Inovio Pharmaceuticals (INO)

(Delayed Data from NSDQ)

$1.49 USD

1.49
1,279,561

+0.05 (3.47%)

Updated Aug 12, 2025 04:00 PM ET

After-Market: $1.41 -0.08 (-5.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (141 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Benjamin Rains headshot

3 Stocks Under $10 That Surged Today

by Benjamin Rains

Here at Zacks, we encourage investors to follow our proven stock-picking system, which places a great deal of emphasis on the importance of earnings estimate revisions in order to identify winning stocks. However, we also always look to cover stocks, from S&P 500 powers to small cap-firms, when they make newsworthy moves.

    Zacks Equity Research

    Inovio Amends Chinese Deal for Immunotherapy, Shares Up

    by Zacks Equity Research

    Inovio (INO) entered into an amended agreement with ApolloBio Corporation and grants ApolloBio the exclusive right to develop and commercialize VGX-3100 within Greater China.

      Zacks Equity Research

      Inovio (INO) Down 15.5% Since Earnings Report: Can It Rebound?

      by Zacks Equity Research

      Inovio (INO) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Zacks Equity Research

        What's in the Cards for Merck KGaA (MKGAF) in Q3 Earnings?

        by Zacks Equity Research

        Merck's (MKGAF) Healthcare and Life Science segments are expected to drive third-quarter sales. The company is progressing with its oncology drug, Bavencio and is also focusing on streamlining its business.

          Zacks Equity Research

          5 Biotech Stocks Well Poised to Surpass Expectations in Q3

          by Zacks Equity Research

          The pharma and biotech industry has demonstrated strength

            Zacks Equity Research

            Puma (PBYI) Q3 Earnings: Will it Surpass Estimates Again?

            by Zacks Equity Research

            Puma Biotechnology's (PBYI) only marketed product, Nerlynx (neratinib), for advanced breast cancer was launched in August. So Q3 is the first quarter in which Puma will record sales for Nerlynx.

              Zacks Equity Research

              BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?

              by Zacks Equity Research

              BioDelivery Sciences (BDSI) has been focusing on growth territories and expanding Bunavail's label. However, the extent to which these impact third-quarter results remains to be seen.

                Zacks Equity Research

                Inovio Initiates Bladder Cancer Study With Roche's Tecentriq

                by Zacks Equity Research

                Inovio Pharmaceuticals (INO) will evaluate a combination of checkpoint inhibitor and T cell activator as a potential treatment for advanced bladder cancer in a new early stage study.

                  Zacks Equity Research

                  Surging Earnings Estimates Signal Good News for Inovio (INO)

                  by Zacks Equity Research

                  Inovio Pharmaceuticals (INO) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.

                    Zacks Equity Research

                    Inovio (INO) Q2 Earnings: What Lies Ahead for the Stock?

                    by Zacks Equity Research

                    Inovio Pharmaceuticals' (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q2. However, lack of an approved product in portfolio is a dampener.

                      Zacks Equity Research

                      Why Is Inovio (INO) Up 21.3% Since the Last Earnings Report?

                      by Zacks Equity Research

                      Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                        Zacks Equity Research

                        Inovio (INO) Stock Rises on Encouraging HIV Vaccine Data

                        by Zacks Equity Research

                        Inovio Pharmaceuticals Inc. (INO) shares have rallied 12% since the company announced that its HIV vaccine evoked almost 100% immune response rates in a clinical study

                          Zacks Equity Research

                          What's in the Cards for Inovio (INO) This Earnings Season?

                          by Zacks Equity Research

                          Inovio Pharmaceuticals, Inc. (INO) is scheduled to report first-quarter 2017 results, after market closes. The company incurred wider-than-expected loss in the last quarter.

                            Zacks Equity Research

                            Why Is Inovio (INO) Down 2% Since the Last Earnings Report?

                            by Zacks Equity Research

                            Inovio Pharmaceuticals (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                              Zacks Equity Research

                              Inovio (INO): What's in the Cards this Earnings Season?

                              by Zacks Equity Research

                              Inovio Pharmaceuticals, Inc. (INO) is expected to report fourth-quarter 2016 results this month. The company incurred wider-than-expected loss in the last quarter.

                                Mark Vickery headshot

                                Zika Virus and Today's Stock Market

                                by Mark Vickery

                                As Inovio Pharma (INO) works to eradicate the Zika virus on U.S. shores and beyond, what does it mean for Florida companies like Disney (DIS), which reported higher quarterly results?